睿知中国医院研究地图
候选清单

长沙中南大学湘雅

中南大学湘雅三医院

Third Xiangya Hospital

在本站收录的 53 种疾病中,这家医院列在其中 21 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

中南大学湘雅三医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma19 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma41 篇牵头论文
  3. 胃癌Stomach cancer17 篇牵头论文
  4. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  5. 脊索瘤Chordoma1 篇牵头论文
  6. 骨肉瘤Osteosarcoma24 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma19 篇牵头论文
  9. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
  10. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis6 篇牵头论文
  11. 血友病 AHaemophilia A0 篇牵头论文
  12. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  13. 重症肌无力Myasthenia gravis3 篇牵头论文
  14. 特发性肺纤维化Idiopathic pulmonary fibrosis12 篇牵头论文
  15. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis5 篇牵头论文
  16. 庞贝病Pompe disease0 篇牵头论文
  17. 白塞病Behçet disease1 篇牵头论文
  18. Alport 综合征Alport syndrome0 篇牵头论文
  19. IgA 肾病IgA nephropathy4 篇牵头论文
  20. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  21. Leber 遗传性视神经病变Leber hereditary optic neuropathy0 篇牵头论文

未列出的收录疾病:食管鳞状细胞癌、肝母细胞瘤、胃肠道间质瘤、尤文肉瘤、再生障碍性贫血、β 地中海贫血、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、杜氏肌营养不良、戈谢病、尼曼-匹克病 C 型、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.8%。

牵头论文
19
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 6620232024: 5520242025: 332025

长沙有 6 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
    分期
    II期
    开始
    2025-01
    登记号
    NCT06788002

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:湖南省肿瘤医院;另有 2 家列出的医院为研究中心长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫治疗诱导/同步化疗复发与转移
论文中的科室耳鼻喉/头颈外科肿瘤内科病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文19
  1. Immune archetypes TIME classification system for nasopharyngeal carcinoma: A new direction for precision immunotherapy.2025Biochimica et biophysica acta. Reviews on cancer
  2. BRD7 Inhibited Immune Escape in Nasopharyngeal Carcinoma via Inhibiting PD-L1 Expression.2025International journal of biological sciences免费全文
  3. Targeting ALG3/FOXD1/BNIP3 Axis Prevents Mitophagy and Gemcitabine Resistance of Nasopharyngeal Carcinoma.2025International journal of biological sciences免费全文
  4. PLUNC inhibits invasion and metastasis in nasopharyngeal carcinoma by inhibiting NLRP3 inflammasome activation.2024Biochimica et biophysica acta. Molecular basis of disease
  5. Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2.2024Cell communication and signaling : CCS免费全文
  6. Neutrophil-to-lymphocyte ratio and monocyte-to-eosinophil ratio as prognostic indicators for advanced nasopharyngeal carcinoma.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  7. APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1.2024International immunopharmacology
  8. TRAF4 regulates ubiquitination-modulated survivin turnover and confers radioresistance.2024International journal of biological sciences免费全文
  9. MicroRNA-101-3p inhibits nasopharyngeal carcinoma cell proliferation and cisplatin resistance through ZIC5 down-regulation by targeting SOX2.2023Biological chemistry
  10. Exosomes loaded with circPARD3 promotes EBV-miR-BART4-induced stemness and cisplatin resistance in nasopharyngeal carcinoma side population cells through the miR-579-3p/SIRT1/SSRP1 axis.2023Cell biology and toxicology
  11. circRNA_0067717 promotes paclitaxel resistance in nasopharyngeal carcinoma by acting as a scaffold for TRIM41 and p53.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  12. Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma.2023Cellular signalling
  13. The immune escape mechanism of nasopharyngeal carcinoma.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  14. LncRNA SNHG1 promotes nasopharyngeal carcinoma development via targeting miR-424-5p.2023Histology and histopathology
  15. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway.2022Journal of translational medicine免费全文
  16. Genetic profile identification and clinicopathologic characteristics analysis of the thyroid-like low-grade nasopharyngeal papillary adenocarcinoma.2022Pathology, research and practice
  17. Identification of four key biomarkers and small molecule drugs in nasopharyngeal carcinoma by weighted gene co-expression network analysis.2021Bioengineered免费全文
  18. Transcription factor STAT1 promotes the proliferation, migration and invasion of nasopharyngeal carcinoma cells by upregulating LINC01160.2021Future oncology (London, England)
  19. Reply: Diagnostic value of exosomal circMYC in radioresistant nasopharyngeal carcinoma: Methodological issues.2021Head & neck
中文论文(未计入)2
  1. Analysis and projection of the disease burden of nasopharyngeal carcinoma in China based on the GBD database.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  2. HDAC6-mediated deacetylation of FLOT2 maintains stability and tumorigenic function of FLOT2 in nasopharyngeal carcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Intestinal Flora Sequencing for Nasopharyngeal Carcinoma已完成NCT04094545牵头方2018-08 启动
  2. LDRT and Chemoimmunotherapy in NPC With Liver Metastasis正在招募NCT06788002研究中心II期2025-01 启动
PubMed 以外找到的论文(未计入)4
  1. Bionic nanobombs target nasopharyngeal carcinoma to enhance the efficacy of chemoradiotherapy by destroying DNA damage repair systems2025Open Research (University of Surrey)论文
  2. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figshare数据集
  3. Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L12023未列出期刊其他
  4. The microRNA-451a/chromosome segregation 1-like axis suppresses cell proliferation, migration, and invasion and induces apoptosis in nasopharyngeal carcinoma2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 41 篇,占 0.3%。

牵头论文
41
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 7720222023: 101020232024: 8820242025: 992025

长沙有 6 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、大连、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室影像/核医学科肿瘤内科普外/肝胆胰外科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文41
  1. Detection of macrotrabecular-massive hepatocellular carcinoma based on viscoelastic characteristics obtained by multifrequency magnetic-resonance elastography.2026European radiology免费全文
  2. MicroRNA-6069 ASO inhibits the growth of hepatocellular carcinoma by PLEKHO1.2025Biochimica et biophysica acta. General subjects
  3. Analysis of influencing factors for achieving textbook outcome after laparoscopic right posterior sectionectomy of hepatocellular carcinoma.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  4. The role of solute carrier family 16 member 3 protein in hepatocellular carcinoma and sorafenib resistance.2025International journal of biological macromolecules
  5. Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score matching and inverse probability weighting analysis.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  6. Liver B Cells Promotes MASLD Progression via the Apelin/APLNR System.2025International journal of medical sciences免费全文
  7. Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma.2025Journal for immunotherapy of cancer免费全文
  8. Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma.2025Journal of experimental & clinical cancer research : CR免费全文
  9. Gene expression profile of anoikis reveals new subtypes of liver cancer and discovery of therapeutic targets and biomarkers.2025Scientific reports免费全文
  10. Exploration of safety indicators for radiotherapy in hepatocellular carcinoma: A real-world study.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  11. Pan-cancer analysis of LRRC59 with a focus on prognostic and immunological roles in hepatocellular carcinoma.2024Aging免费全文
  12. SEH1L siliencing induces ferroptosis and suppresses hepatocellular carcinoma progression via ATF3/HMOX1/GPX4 axis.2024Apoptosis : an international journal on programmed cell death免费全文
  13. Lactic acid: The culprit behind the immunosuppressive microenvironment in hepatocellular carcinoma.2024Biochimica et biophysica acta. Reviews on cancer
  14. ZMAT2 condensates regulate the alternative splicing of TRIM28 to reduce cellular ROS accumulation, thereby promoting the proliferation of HCC cells.2024Cell communication and signaling : CCS免费全文
  15. Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma.2024Current medicinal chemistry
  16. Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.2024Hepatology international
  17. Circ ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 increases the stability of G9a and ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 messenger RNA through recruiting eukaryotic 2024Journal of gastroenterology and hepatology
  18. Identification of MTCH1 as a novel prognostic indicator and therapeutic target in hepatocellular carcinoma.2024Pathology, research and practice
  19. ADNP is associated with immune infiltration and radiosensitivity in hepatocellular carcinoma for predicting the prognosis.2023BMC medical genomics免费全文
  20. Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma.2023Biochemical genetics
  21. PCMT1 is a potential target related to tumor progression and immune infiltration in liver cancer.2023European journal of medical research免费全文
  22. A web-based nomogram model for predicting the overall survival of hepatocellular carcinoma patients with external beam radiation therapy: A population study based on SEER database and a Chinese cohort.2023Frontiers in endocrinology免费全文
  23. The impact of liver fibrosis on the progression of hepatocellular carcinoma via a hypoxia-immune-integrated prognostic model.2023International immunopharmacology
  24. Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma.2023Journal of nanobiotechnology免费全文
  25. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.2023PeerJ免费全文
  26. CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma.2023Radiology
  27. A novel approach for the analysis of single-cell RNA sequencing identifies TMEM14B as a novel poor prognostic marker in hepatocellular carcinoma.2023Scientific reports免费全文
  28. Anoikis-related signature in liver hepatocellular carcinoma defines the YBX1/SPP1 axis by machine learning strategies and valid experiments.2023The journal of gene medicine
  29. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  30. CircCBFB is a mediator of hepatocellular carcinoma cell autophagy and proliferation through miR-424-5p/ATG14 axis.2022Immunologic research
  31. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.2022International journal of biological sciences免费全文
  32. SRSF10 stabilizes CDC25A by triggering exon 6 skipping to promote hepatocarcinogenesis.2022Journal of experimental & clinical cancer research : CR免费全文
  33. Circular RNA circ_GLIS2 suppresses hepatocellular carcinoma growth and metastasis.2022Liver international : official journal of the International Association for the Study of the Liver
  34. PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma.2022Oncogene
  35. Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model.2022World journal of surgical oncology免费全文
  36. TIGIT/PVR and LncRNA ANRIL dual-targetable PAMAM polymeric nanoparticles efficiently inhibited the hepatoma carcinoma by combination of immunotherapy and gene therapy.2021Journal of drug targeting
  37. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta-analysis.2021Liver international : official journal of the International Association for the Study of the Liver
  38. Bcl-2 Associated Athanogene 2 (BAG2) is Associated With Progression and Prognosis of Hepatocellular Carcinoma: A Bioinformatics-Based Analysis.2021Pathology oncology research : POR免费全文
  39. Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma.2021Radiology
  40. Enhanced Chemodynamic Therapy and Chemotherapy via Delivery of a Dual Threat ArtePt and Iodo-Click Reaction Mediated Glutathione Consumption.2021Small methods
  41. Crosstalk between lncRNA DANCR and miR-125b-5p in HCC cell progression.2021Tumori
中文论文(未计入)5
  1. SPP2 plays a role in the tumorigenesis of hepatocellular carcinoma: A bioinformatic based analysis.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  2. Construction of web-based prediction nomogram models for cancer-specific survival in patients at stage IV of hepatocellular carcinoma depending on SEER database.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesRCT免费全文
  3. Effect of miRNA-200b on the proliferation of liver cancer cells via targeting SMYD2/p53 signaling pathway.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  4. Influence of different region of interest sizes on CT-based radiomics model for microvascular invasion prediction in hepatocellular carcinoma.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesRCT免费全文
  5. [MicroRNA-424 inhibits autophagy and proliferation of hepatocellular carcinoma cells by targeting ATG14].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma状态不明NCT03614546牵头方不分期2018-10 启动
  2. TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.状态不明NCT04417764牵头方(推断)I期2019-06 启动
  3. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  4. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma已完成NCT05864105研究中心II期2022-04 启动
  5. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma已终止NCT05653427研究中心II期2022-12 启动
  6. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  7. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  8. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  9. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  10. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  11. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动
  12. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma已完成NCT01988493研究中心I/II期2014-01 启动
  13. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC状态不明NCT03313596研究中心III期2013-03 启动
  14. A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection已终止NCT01402908研究中心III期2011-08 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 17 篇,占 0.2%。

牵头论文
17
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 4420222023: 5520232024: 0020242025: 882025

长沙有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    分期
    不分期
    开始
    2022-09
    登记号
    NCT05450835

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院;另有 7 家列出的医院为研究中心广州、汕头、沈阳、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题早期发现与内镜影像与人工智能腹膜转移与晚期
论文中的科室消化/肝病科耳鼻喉/头颈外科儿科
牵头的论文17
  1. Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis.2025Biochimica et biophysica acta. Reviews on cancer
  2. AKR1B1 Inhibits Ferroptosis and Promotes Gastric Cancer Progression via Interacting With STAT3 to Activate SLC7A11.2025Cell biology international
  3. Circular RNA TFRC/SCD1 mRNA interaction regulates ferroptosis and metastasis in gastric cancer.2025Cell death & disease免费全文
  4. Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System.2025Clinical nuclear medicine
  5. Metabolic reprogramming in Helicobacter pylori infection: from mechanisms to therapeutics.2025Frontiers in cellular and infection microbiology免费全文
  6. TRAF1 promotes the progression of Helicobacter pylori-associated gastric cancer through EGFR/STAT/OAS signalling.2025Life sciences
  7. VacA promotes pyroptosis via TNFAIP3/TRAF1 signaling to induce onset of atrophic gastritis.2025Microbiological research
  8. The expression signature, prognostic significance and immune cell infiltration of the OAS gene family in gastric cancer.2025Scientific reports免费全文
  9. Construction of a lipid metabolism-related and immune-associated prognostic score for gastric cancer.2023BMC medical genomics免费全文
  10. LHPP promotes the intracellular reactive oxygen species accumulation and sensitivity of gastric cancer to cisplatin via JNK and p38 MAPK pathways.2023Histology and histopathology
  11. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.2023PeerJ免费全文
  12. Comprehensive analysis of COMMD10 as a novel prognostic biomarker for gastric cancer.2023PeerJ免费全文
  13. Clinicopathological and prognostic significance of LKB1 expression in gastric cancer: a systematic review and meta-analysis.2023Scientific reports免费全文
  14. Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.2022BMJ open免费全文
  15. A deep learning method to assist with chronic atrophic gastritis diagnosis using white light images.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  16. The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019.2022Scientific reports免费全文
  17. The impact of robotic technology on the learning curve for robot-assisted gastrectomy in the initial clinical application stage.2022Surgical endoscopy
中文论文(未计入)3
  1. Clinical characteristics of non-HPV infection-associated gastric-type endocervical adenocarcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  2. Comparison of the learning curve of robot-assisted and laparoscopic-assisted gastrectomy.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  3. Risk factors for complications of therapeutic endoscopy for upper gastrointestinal subepithelial lesions.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Domestic Surgical Robot Clinical Study状态不明NCT02752698牵头方不分期2015-01 启动
  2. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method正在招募NCT05450835研究中心不分期2022-09 启动
  3. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

长沙有 6 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

长沙有 6 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 24 篇,占 1.1%。

牵头论文
24
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 1120222023: 3320232024: 111120242025: 552025

长沙有 10 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科普外/肝胆胰外科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文24
  1. Development of a prognostic model for osteosarcoma based on macrophage polarization-related genes using machine learning: implications for personalized therapy.2025Clinical and experimental medicine
  2. Single-cell analysis links DCUN1D5 to immune remodeling and cisplatin resistance in recurrent osteosarcoma.2025Communications biology
  3. m6A methylation modification: Potential pathways to suppress osteosarcoma metastasis.2025International immunopharmacology
  4. Biopolymer-based bone scaffold for controlled Pt (IV) prodrug release and synergistic photothermal-chemotherapy and immunotherapy in osteosarcoma.2025Journal of nanobiotechnology
  5. Decoding the role of SLC25A5 in osteosarcoma drug resistance and CD8+ T cell exhaustion: The therapeutic potential of phyllanthin.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. Single-Atom Cu Nanozyme-Loaded Bone Scaffolds for Ferroptosis-Synergized Mild Photothermal Therapy in Osteosarcoma Treatment.2024Advanced healthcare materials
  7. The Targeted Therapies for Osteosarcoma via Six Major Pathways.2024Current molecular pharmacology
  8. RNA modification-related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single-cell sequencing analysis.2024Environmental toxicology
  9. Identification of an ADME-related gene for forecasting the prognosis and responding to immunotherapy in sarcomas.2024European journal of medical research
  10. Single-cell RNA-seq reveals T cell exhaustion and immune response landscape in osteosarcoma.2024Frontiers in immunology
  11. METTL16 promotes osteosarcoma progression by downregulating VPS33B in an m6 A-dependent manner.2024Journal of cellular physiology
  12. M2 macrophage exosome-derived Apoc1 promotes ferroptosis resistance in osteosarcoma by inhibiting ACSF2 deubiquitination.2024Molecular carcinogenesis
  13. Bruceantinol targeting STAT3 exerts promising antitumor effects in in vitro and in vivo osteosarcoma models.2024Molecular carcinogenesis
  14. Disulfidptosis-related PABPC3 promotes tumor progression and inhibits immune activity in osteosarcoma.2024The journal of gene medicine
  15. Diverse cell death patterns-related signature for predicting prognosis and drug sensitivity of osteosarcoma patients.2024The journal of gene medicine
  16. Antigen processing and presentation-related signature-derived BNIP3 is a novel oncogene and immunotherapy determinant in osteosarcoma based on machine learning and in vitro validation.2024The journal of gene medicine
  17. Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma.2023Frontiers in immunology
  18. Prognosis-related VDAC1 regulates the proliferation and apoptosis of osteosarcoma cells via the MAPK signaling pathway.2023Genomics
  19. Exosomal miR-181a-5p derived from SAOS-2 cells promotes macrophages M2 polarization by targeting RORA.2023The Kaohsiung journal of medical sciences
  20. RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma.2022Journal of translational medicine
  21. A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects.2021ACS applied materials & interfaces
  22. Effect of the Notch1-mediated PI3K-Akt-mTOR pathway in human osteosarcoma.2021Aging
  23. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.2021Frontiers in immunology
  24. LncRNA-ROR/microRNA-185-3p/YAP1 axis exerts function in biological characteristics of osteosarcoma cells.2021Genomics
中文论文(未计入)1
  1. Prognositic value of anoikis and tumor immune microenvironment-related gene in the treatment of osteosarcoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
早期论文(2016–2020 年)14
  1. WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m6A-dependent manner.2020Cell death & disease
  2. miR-485-5p/HSP90 axis blocks Akt1 phosphorylation to suppress osteosarcoma cell proliferation and migration via PI3K/AKT pathway.2020Journal of physiology and biochemistry
  3. LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis.2020Molecular medicine (Cambridge, Mass.)
  4. High SENP3 Expression Promotes Cell Migration, Invasion, and Proliferation by Modulating DNA Methylation of E-Cadherin in Osteosarcoma.2020Technology in cancer research & treatment
  5. Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway.2019Journal of cellular and molecular medicine
  6. Interleukin-1β/nuclear factor-κB signaling promotes osteosarcoma cell growth through the microRNA-181b/phosphatase and tensin homolog axis.2019Journal of cellular biochemistry
  7. miR-194 Suppresses Proliferation and Migration and Promotes Apoptosis of Osteosarcoma Cells by Targeting CDH2.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  8. miR-24 represses metastasis of human osteosarcoma cells by targeting Ack1 via AKT/MMPs pathway.2017Biochemical and biophysical research communications
  9. IL-1β-induced NF-κB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  10. Primary osteosarcoma of frontal bone: A case report and review of literature.2017Medicine
  11. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.2017Oncotarget
  12. The tumor suppressive role of RASSF1A in osteosarcoma through the Wnt signaling pathway.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  13. [MicroRNA-150 inhibits osteosarcoma cell proliferation by targeting RUNX2 gene].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  14. [miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

长沙有 7 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 19 篇,占 1.1%。

牵头论文
19
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 0020222023: 7720232024: 4420242025: 552025

长沙有 4 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题联合用药复发与耐药CAR-T 与细胞治疗
牵头的论文19
  1. Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8+ T-Cell-Mediated Immunity against Multiple Myeloma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies.2025Cancer immunology, immunotherapy : CII免费全文
  3. MIR4726EccDNA drives bortezomib resistance in multiple myeloma by enhancing MIR4726-5p/NXF1/NKIRAS2 axis dependent autophagy.2025Cell communication and signaling : CCS免费全文
  4. Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferroptosis genes.2025Hematology (Amsterdam, Netherlands)
  5. Exosomal tRF-1003 induces angiogenesis via regulating the HIF1α/VEGF signaling in multiple myeloma.2025International immunopharmacology
  6. Multiple myeloma exosomal miRNAs suppress cGAS-STING antiviral immunity.2024Biochimica et biophysica acta. Molecular basis of disease
  7. Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.2024Current treatment options in oncology
  8. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.2024International immunopharmacology
  9. BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.2024Journal of translational medicine免费全文
  10. The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib.2023Chemico-biological interactions
  11. Exosomal miR-21-5p derived from multiple myeloma cells promote renal epithelial-mesenchymal transition through targeting TGF-β/SMAD7 signalling pathway.2023Clinical and experimental pharmacology & physiology
  12. Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.2023European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  13. CD38-targeted and erythrocyte membrane camouflaged nanodrug delivery system for photothermal and chemotherapy in multiple myeloma.2023International journal of pharmaceutics
  14. Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life?2023Journal of clinical nursing
  15. IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma.2023Scientific reports免费全文
  16. The core symptom in multiple myeloma patients undergoing chemotherapy: a network analysis.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer免费全文
  17. Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.2021Annals of hematology免费全文
  18. tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma.2021BMC bioinformatics免费全文
  19. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.2021International journal of medical sciences免费全文
中文论文(未计入)4
  1. Clinical significance of CD45 and CD200 expression in newly diagnosed multiple myeloma patients.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  2. Construction of a treatment response prediction model for multiple myeloma based on multi-omics and machine learning.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  3. Diagnosis and treatment of multiple myeloma in Hunan Province.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
  4. Research progress in proteasome inhibitor resistance to multiple myeloma.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  2. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  3. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  4. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  5. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)状态不明NCT05066646研究中心I/II期2020-04 启动
  6. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  7. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma已完成NCT04121260研究中心I期2019-12 启动
  8. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma已完成NCT03944057研究中心II期2019-09 启动
  9. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

长沙有 4 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-01
    登记号
    NCT06764238

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛

  2. 正在招募
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06882057

    年龄 1 岁 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛

  3. 正在招募
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    分期
    III期
    开始
    2025-03
    登记号
    NCT07152041

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 20 家列出的医院为研究中心上海、南京、南昌、天津、广州、成都、武汉、济南、深圳、福州、苏州、贵阳、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题费城染色体与遗传学儿童抗体与靶向药物

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.5%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 2220232024: 0020242025: 222025

长沙有 4 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题治疗方案EB病毒与感染诱因儿童
论文中的科室儿科普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 6 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

长沙有 5 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

长沙有 4 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题常规免疫治疗生物制剂与补体抑制剂抗体与诊断
论文中的科室儿科
牵头的论文3
  1. Statin‑associated myasthenia gravis: a real-world retrospective and pharmacovigilance study.2026Expert opinion on drug safety
  2. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis.2023Clinical and experimental immunology
  3. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.2023Investigational new drugs
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 12 篇,占 1.2%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 4420232024: 2220242025: 222025

长沙有 6 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科
牵头的论文12
  1. A Rare TERT Mutation Associated with Idiopathic Pulmonary Fibrosis and COPD in a Chinese Family.2025Balkan medical journal
  2. Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages.2025International immunopharmacology
  3. Identification of key mitochondria-related genes and their potential crosstalk role with immune pattern in Idiopathic pulmonary fibrosis.2024Gene
  4. Succinate promotes pulmonary fibrosis through GPR91 and predicts death in idiopathic pulmonary fibrosis.2024Scientific reports
  5. Identification of the shared genes and immune signatures between systemic lupus erythematosus and idiopathic pulmonary fibrosis.2023Hereditas
  6. Establishment and application of the BRP prognosis model for idiopathic pulmonary fibrosis.2023Journal of translational medicine
  7. Ectopic and visceral fat deposition in aging, obesity, and idiopathic pulmonary fibrosis: an interconnected role.2023Lipids in health and disease
  8. S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function.2023Pulmonary pharmacology & therapeutics
  9. The Combined Model of CX3CR1-Related Immune Infiltration Genes to Evaluate the Prognosis of Idiopathic Pulmonary Fibrosis.2022Frontiers in immunology
  10. Retrospective analysis of skin photosensitivity induced by pirfenidone.2022Journal of clinical pharmacy and therapeutics
  11. The networks of m6A-SARS-CoV-2 related genes and immune infiltration patterns in idiopathic pulmonary fibrosis.2021Aging
  12. Investigation of a Hypoxia-Immune-Related Microenvironment Gene Signature and Prediction Model for Idiopathic Pulmonary Fibrosis.2021Frontiers in immunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis即将招募NCT07909655研究中心II期2026-11 启动
  2. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  3. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04594707研究中心III期2021-08 启动
  4. Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults已完成NCT03619616研究中心I期2018-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.6%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025

长沙有 4 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

庞贝病

Pompe disease

2021–2025 年没有牵头庞贝病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 2 家医院列在庞贝病下全国有 30 家医院列在庞贝病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Clinical characteristics and GAA gene mutation in children with glycogen storage disease type II: an analysis of 3 cases].2017Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

长沙有 3 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年没有牵头Alport 综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 3 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 3320232024: 0020242025: 002025

长沙有 7 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    分期
    III期
    开始
    2025-07
    登记号
    NCT06963827

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科消化/肝病科临床试验/研究机构
牵头的论文4
  1. Inflammatory bowel disease increases the levels of albuminuria and the risk of urolithiasis: a two-sample Mendelian randomization study.2023European journal of medical research
  2. Prognostic value of low-density lipoprotein cholesterol in IgA nephropathy and establishment of nomogram model.2023Frontiers in endocrinology
  3. Iron metabolism and chronic inflammation in IgA nephropathy.2023Renal failure
  4. A Mendelian randomization study to assess the genetic liability of type 1 diabetes mellitus for IgA nephropathy.2022Frontiers in endocrinology
早期论文(2016–2020 年)2
  1. CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?2017Current gene therapy
  2. Identification of a novel collagen type IV alpha-4 (COL4A4) mutation in a Chinese family with autosomal dominant Alport syndrome using exome sequencing.2016The Indian journal of medical research
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy正在招募NCT06963827研究中心III期2025-07 启动
  2. A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases进行中,不再招募NCT06786338研究中心II期2025-06 启动
  3. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  4. Atrasentan in Patients With IgA Nephropathy进行中,不再招募NCT04573478研究中心III期2020-12 启动
  5. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 4 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. COL1A2 p.Gly1066Val variant identified in a Han Chinese family with osteogenesis imperfecta type I.2019Molecular genetics & genomic medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年没有牵头Leber 遗传性视神经病变的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

长沙有 1 家医院列在Leber 遗传性视神经病变下全国有 30 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Identification of an ND4 Mutation in Leber Hereditary Optic Neuropathy.2017Optometry and vision science : official publication of the American Academy of Optometry

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

中南大学湘雅三医院

Third Xiangya Hospital

长沙

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Third Xiangya Hospital of Central South University; Central South University Third Xiangya Hospital; Transplantation Center of the Third Xiangya Hospital; Third XiangYa Hospital; 中南大学湘雅三医院-门急诊楼

提出更正下载数据